Get started

Health

Nabriva - Strong Potential 💪-Nabriva Therapeutics (NASDAQ:NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results. -In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for moxifloxacin. -Also, Sinovant inked an agreement with a Chinese subsidiary of Sumitomo Dainippon Pharma (OTCPK:DNPUF) to acquire development and commercialization rights for lefamulin in Greater China. Nabriva shares are up 40.5% to $2.08 in after-hours trading.
NLong
by caldooninvestment
15
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken
Exela Technologies Wins $90 Million ContractExela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital transformation efforts for a major US health insurance company and is part of a broader relationship that included over $28 million in revenue in 2020. finance.yahoo.com
X
by AlenCiken
DaVitaCorporate Profile DaVita is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients around the globe. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage renal disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. As of June 30, 2020, DaVita served 205,000 patients at 2,795 outpatient dialysis centers in the United States. The company also operated 287 outpatient dialysis centers in ten countries across the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. There are like 5 of these within every mile in Chicago lol It's inevitable lol *not investing advice Today, DaVita Kidney Care announced that more than 100,000 DaVita patients have received a kidney transplant since 2000. This milestone represents the culmination of two decades of innovative strategies spearheaded by the kidney care provider to increase patient education and access to kidney transplantation. DaVita Kidney Care (PRNewsfoto/DaVita Kidney Care) "We are deeply committed to helping every interested patient be evaluated by transplant centers and stay transplant ready," said Dr. Jeff Giullian, chief medical officer for DaVita. "Transplant is the best option for most patients with kidney failure, as it's the only way for these patients to live without relying on dialysis." According to the United Network for Organ Sharing (UNOS), 24,273 people received a kidney transplant in the United States in 2019. More than 6,000 DaVita patients have already received a transplant in 2020, despite the many setbacks transplant programs faced due to COVID-19. At the same time, nearly 100,000 people in the United States remain on a kidney transplant waitlist. The average wait for a non-living kidney donor match is 3.6 years. The Advancing American Kidney Health initiative launched in 2019 calls for doubling the number of kidneys available for transplant by 2030. The initiative lays out a roadmap to help organ procurement organizations and transplant centers reach this goal, which aligns with DaVita's longstanding work to empower all patients to choose to be evaluated for transplant. My name is Ski Mask and I've been making bad decision all my life. Strike Price: $109.35 Like Follow Agree Disagree! What do you think?
NYSE:DVALong
by Redimere_91
VERY headed to a new all time high? This stock has been CSE:VERY good to me. The Very Good Food Company makes Vegan Meats better than Beyond and all the other meat wannabes CSE:VERY I first 'bought in' to this company when I tried my first vegan faux breakfast sandwich at their first and only eat-in location in Victoria, Canada. I put my money where my mouth was when I bought into them soon after their IPO at $1.09. Since then, their market cap has exploded to 640m and so has demand for their products. They are rapidly scaling up production to meet an even more rapidly growing demand, with an 82% production capacity improvement since OCTOBER 2020. They recently acquired a small nut-based vegan cheese company to expand their product offerings. Bullish press releases and strong technicals continue to push this stock up. I wouldn't be surprised if an uplisting to the NASDAQ is in their future. A close over 9.50 above their previous all-time highs will be breaking out of a final resistance point could be a good entry with a lot of upside. I am hanging on to what is left of my original position and don't intend on exiting anytime soon, this is a long term hold for me. DISCLAIMER: This is not to be interpreted as trading advice.
VLong
by matrixmisfit
4
Nova Leap Health Corp (NLH)Executive Summary Nova Leap Health is a consolidator of an extremely fragmented space of home care and home health care agencies. Nova Leap buys them at ~5x EBITDA and subsequently improves EBITDA margin. As the company scales its operations, the operating leverage would lead to margin expansion. The stock price has an upside of ~100% in 1 year. Opportunity 1) Small Cap (50m) 2) Sell side has not discovered it yet 3) Flying under the radar Nova presently has a $2.1m cash pile and a long term debt of $2.7m, debt was $5.3M in August with a $2.7M cash pile Business Overview NLH is home care and home health care services company operating in Vermont, New Hampshire, Massachusetts, Rhode Island, Oklahoma, Ohio, and Nova Scotia. NLH all entered into all these markets (except for Ohio) through M&A transactions. Home care covers such activities as: Dementia care Personal grooming like bathing or getting dressed Moving around: getting in and out of the bed/shower Medication reminders Errands like grocery shopping and picking up prescriptions Light housekeeping Meal preparation Home healthcare covers such activities as: Skilled nursing At-home physical therapy Pain Management Caring for wounds Prescription management Customer Value Proposition Home care and home healthcare enables senior citizens to stay in their homes even after they cannot live completely on their own. Homecare crates a buffer from when a senior citizen needs to move to a nursing facility COVID-19 Tailwind Senior citizens living at nursing facilities suffered greatly from COVID-19. There were instances where a big part of a nursing home’s population got infected by COVID-19. Second, many senior citizens got locked down at nursing facilities and were not able to see family members for very extended periods of time for safety reasons. Needless to say, that was a real hardship. Thus, I expect that both senior citizens and their families (e.g., children) would be trying to avoid or at least delay moving to a nursing facility as long as possible which would provide strong tailwinds for home care industry and Nova Leap. M&A Strategy 1. M&A Criteria Nova Leap has the following acquisition criteria: 1) U.S. and Canada geographic focus 2) Positive EBITDA with strong reputation/brand 3) Normally 5+ year history 4) Opportunities for operational synergies 5) $1M-$15M of Revenues Nova Leap is going after targets that are too small for private equity players and as a result faces limited competition. The space is very fragmented, and Nova Leap has many potential acquisition targets in front of it. M&A Playbook and Integration Nova Leap buys home care businesses that are primarily private pay. After that Nova Leap makes incremental changes at the acquired operations. First, Nova Leap implements price increases where it is appropriate. Second, Nova Leap reducea overtime because overtime destroys gross profit margin. Third, Nova Leap consolidates the back-office functions such as accounting. For example, instead of an accountant looking after one agency, such account working at Nova Leap HQ would be looking after 3 or 4 home care agencies. Fourth, better scheduling using scheduling software. Operating Philosophy CEO Chris Dobbin runs Nova Leap in a very decentralized fashion. Most locations’ leaders have lots of autonomy. HQ are responsible for setting up standards and back office / accounting. Chris Dobbin spends his time heavily on M&A and overseeing the agencies’ leaders. Unit Economics The key operating drivers are the number of client service hours and revenue per hour. Revenue per hour has been quite stable and is ~$25. Cost per hour has also been stable: ~$16.50 - $17.00. Thus, the profit per hour is ~$8.50 to $9. Four-Wall Economics and Four-Wall EBITDA “Four-wall EBITDA” is of course a misnomer because there are no tangible walls to speak of, but the concept still applies. I want to analyze profitability of field operations first and then overlay HQ expenses on top of that. The key issue that Nova Leap is facing today is its small size of field operations vs. HQ. However, with a few more acquisitions and de minimis growth in HQ expenses (see more on this below), the operating leverage would kick in and lead to a disproportionate increase in EBITDA. In 2019 segment EBITDA margin (e.g., before HQ costs) was 11.88%. However, in 1Q 2020 and 2Q 2020 it was 10.91% and 10.39% respectively due to the COVID-19 impact. Revenue run-rate (ex-COVID-19) is ~$5M per quarter or ~$20M per year. With ~12% segment EBITDA margin, NLH should be able to generate ~~$2.4M of segment EBITDA. With the EV of ~$19M, the EV/Segment EBITDA is ~7.85x. HQ Operations The HQ team based in Halifax is small and includes CEO, CFO, controller, and business development person. This is purely corporate function. The HQ also has 5 accountants. However, they work with field agencies. Nova Leap wants to do 4 to 6 M&A transactions a year (there was zero during COVID-19 pandemic so 2020 number would probably be lower than this target). Doing these M&A transactions will not require hiring any more HQ personnel. However, Nova Leap would probably need to hire an accountant for every 3-4 acquisitions (maybe 5). HQ expenses are ~$280K - $300K per quarter when there are no M&A transactions. Let’s call it $1.2M per year. Scaling What the numbers above is mean is that Nova Leap needs to get another $1M of EBITDA to show the strength of its operating model. That would probably require $5M of capital. I expect that it will be done with a very small dilution to existing shareholders. Valuation and Upside Potential As I alluded above, current headline multiple of EBITDA is not particularly attractive. However, with getting more scale and proving the model, I would not be surprised if Nova Leap trades at 12x – 14x EBIDA in 1 year could generate a 100% upside Risks M&A Integration M&A integration risks are inherent for any roll up / consolidation strategy and NLH is not exception. 2. Leverage NLH has ~$2.0M of debt which is a lot given its EBITDA today. If NLH does not grow its EBITDA, its leverage can become an issue. Catalysts 1. Continuous M&A 2. Operating leverage showing up as the company continues to scale its operations.
TSXV:NLHLong
by JabroniCapital
1
Community Health Systems Overvalued Those who have been following Community Health Systems since the firm's stock tumbled in October 2016 following the $7.6B merger with HMA may be wondering if the hospital giant has found its footing after three consecutive quarters of being EPS positive, rallying stock prices to a 52-week high record of $11.04/share. Today, I am here to tell you that this stock is very much overpriced compared to the firm's current market value. Highlights (Quarter by Quarter Fundamental Analysis) Short-term assets such as Cash and Cash equivalence have increased again by 17% to 1.8B, while receivables and inventory have decreased, signaling that Community Health Systems could be improving their asset turnover or we will see a decrease in net income next quarter. Total assets have slightly increased while debts have slightly decreased resulting in a 2% decrease in debt-to-assets, however, the firm has continued the trend of financing assets with more debt with a 5% increase in debt-to-equity from 28.1% to 29.5%. CYH also maintains an enterprise value far greater than their market cap value. CYH has continued the trend of cutting SGA expenses. Although we see a reduction in FCF, it remains positive. Using the DCF model, we have a fair-market-value of about $6.30/share. (One-year Chart using Technical Analysis) Upon reviewing the charts, we will most likely see a decline in the stock's price. The RSI and MACD are bearish while the price is testing the 20 EMA. Analyzing the volume, we are seeing that the bulls are starting to lose momentum. Short/put - $5.70 (low confidence) to $6.30 (high confidence)
NYSE:CYHShort
by OrangeTrader93
PTON over 116.92This one has been in an uptrend but faked us out for the past few days with a number of false breakouts. Shown here on the hourly, a break outside this box at the trigger should yield a larger move, especially if it can fill the gap above from 117.75 to 122.49. This gap can be used as a more conservative entry. Bollinger band shows room up to 119 on the daily and 141.11 on the weekly. These are not necessarily targets, but show one standard deviation of movement from the 20EMA S/L 115.08.
NASDAQ:PTONLong
by SpinTrades
JNH Resumes Uptrend? Trade Setup (>100% Potential Profits)Hello Fellow Traders, Here we are looking at Jack Nathan Medical Corp (JNH) on the TSXV. As we can see, this is a relatively new chart which rallied throughout October, reaching a high of $2.72. The price has since corrected and formed a bullish falling wedge pattern. Additionally, following a breakout from the wedge, it has printed a double bottom in the $1.10-$1.15 range. Prices are now trading above the 10, 21, 50 EMAs on the 4H chart. We can see increasing volume, the RSI has risen above 50, and the MACD is increasing as well, all bullish signals. Depending on how quickly this chart picks up, we could see massive growth, so I have marked some potential paths for the next bullish wave. Prices can easily move up from here. In the long term, a breakout past the high of $2.72 would allow for additional growth, with a target at the 1.618 Fib level of $3.70 (+184%). A potential trade setup now may be: Entry: $1.20-$1.40 Targets: $2.10 (+61%) | $2.70 (+107%) | $3.70 (+183%) Stop loss: $1.05 (-20%) Let me know what you think down below and leave a like if you appreciate the analysis. Also, check out my profile or some of the related ideas below and be sure to follow for more chart analyses and profitable trade setups! Price at writing: $1.30
TSXV:JNHLong
by PS_TopDollarInvestments
1